Bayer CV Pact Gives AI-Focused Sensyne Health Its First Big Deal Since 2018 IPO

31 Jul 2019

• By Sten Stovall

The UK-based group will help Bayer accelerate clinical development of new treatments for cardiovascular disease using Sensyne Health’s clinical AI technology platform and NHS data.

Digital_Heart — Pact will use AI to speed and improve clinical trials in heart disease • Source: Shutterstock

Bayer CV Pact Gives AI-Focused Sensyne Health Its First Big Deal Since 2018 IPO

More from Deals

More from Business